Ser75
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser75  -  MAF1 (human)

Site Information
sPsRLsksQGGEEEG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 477954
Available spectra:  8 CST
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 50 ) , electrophoretic mobility shift ( 48 , 52 ) , mass spectrometry ( 1 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 ) , mutation of modification site ( 2 , 48 , 50 , 52 ) , phospho-antibody ( 50 ) , western blotting ( 2 , 48 , 50 , 52 )
Disease tissue studied:
bone cancer ( 52 ) , osteosarcoma ( 52 ) , brain cancer ( 61 ) , glioblastoma ( 61 ) , glioma ( 61 ) , breast cancer ( 5 , 10 , 31 ) , breast ductal carcinoma ( 10 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 ) , cervical cancer ( 53 ) , cervical adenocarcinoma ( 53 ) , gastric cancer ( 28 ) , liver cancer ( 2 ) , lung cancer ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , non-small cell lung cancer ( 13 , 14 , 15 , 17 , 18 , 19 , 22 , 23 , 24 , 25 , 27 , 29 , 30 ) , non-small cell lung adenocarcinoma ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 23 , 25 ) , non-small cell large cell lung carcinoma ( 14 , 17 ) , non-small cell squamous cell lung carcinoma ( 16 , 30 ) , small-cell lung cancer ( 11 , 12 ) , ovarian cancer ( 10 ) , melanoma skin cancer ( 7 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 39 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 49 ) , 293 (epithelial) ( 9 , 52 ) , 293E (epithelial) ( 44 ) , 786-O (renal) [VHL (human), transfection] ( 6 ) , 786-O (renal) ( 6 ) , A498 (renal) ( 51 ) , A549 (pulmonary) ( 13 , 27 ) , breast ( 3 , 10 ) , Cal-12T (pulmonary) ( 19 ) , Calu-3 (pulmonary) ( 15 ) , DMS153 (pulmonary) ( 18 ) , DMS53 (pulmonary) ( 12 ) , DMS79 (pulmonary) ( 11 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 32 ) , Flp-In T-Rex-293 (epithelial) ( 32 ) , GM00200 (fibroblast) ( 68 , 69 ) , GM18366 (fibroblast) ( 70 , 71 ) , HCC15 (pulmonary) ( 16 ) , HCC1937 (breast cell) ( 31 ) , HCC44 (pulmonary) ( 19 ) , HCC78 (pulmonary) ( 17 ) , HCC827 (pulmonary) ( 15 ) , HEK293T (epithelial) ( 2 , 62 ) , HeLa (cervical) [MAF1 (human), transfection] ( 48 ) , HeLa (cervical) ( 8 , 26 , 45 , 46 , 50 , 54 , 56 , 57 , 58 , 59 , 60 ) , HeLa S3 (cervical) ( 53 ) , HepG2 (hepatic) ( 2 ) , HUES-9 ('stem, embryonic') ( 47 ) , IMR90hTERT (fibroblast) [MAF1 (human), transfection] ( 48 ) , Jurkat (T lymphocyte) ( 34 , 35 , 40 , 41 , 42 , 43 , 55 , 63 , 64 , 65 ) , K562 (erythroid) ( 26 , 54 ) , LOU-NH91 (squamous) ( 16 ) , lung ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , M059J (glial) ( 76 , 79 ) , M059K (glial) ( 61 , 66 , 67 , 72 , 73 , 74 , 75 , 77 , 78 ) , MCF-7 (breast cell) ( 5 , 31 ) , MDA-MB-361 (breast cell) ( 52 ) , MEF (fibroblast) ( 2 ) , MEF (fibroblast) [MAF1 (human), transfection] ( 48 ) , MG63 (bone cell) ( 52 ) , MKN-45 (gastric) ( 28 ) , NCI-H128 (pulmonary) ( 11 ) , NCI-H1299 (pulmonary) ( 14 ) , NCI-H1355 (pulmonary) ( 13 ) , NCI-H1417 (pulmonary) ( 11 ) , NCI-H1437 (pulmonary) ( 18 , 19 ) , NCI-H1650 (pulmonary) ( 15 ) , NCI-H1666 (pulmonary) ( 19 ) , NCI-H1703 (squamous) ( 16 , 30 ) , NCI-H1734 (pulmonary) ( 14 ) , NCI-H1781 (pulmonary) ( 17 ) , NCI-H1792 (pulmonary) ( 13 ) , NCI-H1944 (pulmonary) ( 14 ) , NCI-H1975 (pulmonary) ( 15 ) , NCI-H2073 (pulmonary) ( 16 , 18 ) , NCI-H209 (pulmonary) ( 11 , 18 ) , NCI-H2106 (pulmonary) ( 15 ) , NCI-H2228 (pulmonary) ( 17 , 23 , 25 ) , NCI-H23 (pulmonary) ( 13 ) , NCI-H2342 (pulmonary) ( 16 ) , NCI-H2405 (pulmonary) ( 19 ) , NCI-H3122 (pulmonary) ( 17 , 22 , 24 ) , NCI-H3255 (pulmonary) ( 29 ) , NCI-H358 (pulmonary) ( 14 ) , NCI-H441 (pulmonary) ( 13 ) , NCI-H446 (pulmonary) ( 12 ) , NCI-H460 (pulmonary) ( 14 ) , NCI-H524 (pulmonary) ( 11 ) , NCI-H526 (pulmonary) ( 12 ) , NCI-H661 (pulmonary) ( 17 ) , NCI-H69 (pulmonary) ( 12 ) , NCI-H82 (pulmonary) ( 12 ) , NCI-H838 (pulmonary) ( 18 ) , ovary ( 10 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 7 )

Upstream Regulation
Regulatory protein:
mTOR (human) ( 52 )
Kinases, in vitro:
mTOR (human) ( 48 , 50 )
Treatments:
anti-CD3 ( 55 ) , ischemia ( 10 ) , MMS ( 48 ) , nocodazole ( 53 ) , rapamycin ( 2 , 44 , 48 , 50 ) , serum_starvation ( 48 ) , temsirolimus ( 52 ) , Torin1 ( 44 , 48 ) , UV ( 61 , 62 ) , WYE132 ( 52 )

Downstream Regulation
Effects of modification on MAF1:
activity, inhibited ( 48 ) , protein degradation ( 2 ) , ubiquitination ( 2 )
Effects of modification on biological processes:
transcription, altered ( 50 ) , transcription, induced ( 2 , 48 , 52 )

References 

1

Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell
32645325   Curated Info

2

Wang X, et al. (2019) The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates drug resistance and apoptosis. J Biol Chem
31645432   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

5

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

6

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

7

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

8

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

9

Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54
24965592   Curated Info

10

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

16

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

17

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

18

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

19

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

20

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

21

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

22

Rikova K (2013) CST Curation Set: 18531; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

23

Rikova K (2013) CST Curation Set: 18529; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

24

Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

25

Rikova K (2013) CST Curation Set: 18502; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

26

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

27

Rikova K (2012) CST Curation Set: 16148; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

28

Rikova K (2012) CST Curation Set: 16145; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

29

Rikova K (2012) CST Curation Set: 16146; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

30

Rikova K (2012) CST Curation Set: 16147; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

31

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

32

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

33

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

34

Mulhern D (2012) CST Curation Set: 14051; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

35

Mulhern D (2012) CST Curation Set: 14052; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

36

Rikova K (2012) CST Curation Set: 13735; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

37

Rikova K (2012) CST Curation Set: 13736; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

38

Rikova K (2012) CST Curation Set: 13737; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

39

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

40

Mulhern D (2011) CST Curation Set: 13261; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: ATM/ATR substrate (s/t)QG Cat#: 6939
Curated Info

41

Mulhern D (2011) CST Curation Set: 13262; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: ATM/ATR substrate (s/t)QG Cat#: 6939
Curated Info

42

Mulhern D (2011) CST Curation Set: 13263; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: ATM/ATR substrate (s/t)QG Cat#: 6939
Curated Info

43

Mulhern D (2011) CST Curation Set: 13265; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

44

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

45

Zhou J (2011) CST Curation Set: 11707; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

46

Zhou J (2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

47

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

48

Michels AA, et al. (2010) mTORC1 directly phosphorylates and regulates human MAF1. Mol Cell Biol 30, 3749-57
20516213   Curated Info

49

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

50

Kantidakis T, et al. (2010) mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc Natl Acad Sci U S A 107, 11823-8
20543138   Curated Info

51

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

52

Shor B, et al. (2010) Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem 285, 15380-92
20233713   Curated Info

53

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

54

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

55

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

56

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

57

Zhou J (2008) CST Curation Set: 4841; Year: 2008; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993
Curated Info

58

Zhou J (2008) CST Curation Set: 4842; Year: 2008; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993
Curated Info

59

Zhou J (2008) CST Curation Set: 4777; Year: 2008; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993
Curated Info

60

Zhou J (2008) CST Curation Set: 4778; Year: 2008; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993
Curated Info

61

Stokes MP, et al. (2007) Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A 104, 19855-60
18077418   Curated Info

62

Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6
17525332   Curated Info

63

Possemato A (2007) CST Curation Set: 2795; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

64

Possemato A (2007) CST Curation Set: 2796; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993
Curated Info

65

Possemato A (2007) CST Curation Set: 2797; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

66

Stokes M (2006) CST Curation Set: 1956; Year: 2006; Biosample1/Treatment/Isotope: cell line, M059K/normal/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

67

Stokes M (2006) CST Curation Set: 1957; Year: 2006; Biosample1/Treatment/Isotope: cell line, M059K/normal/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

68

Stokes M (2006) CST Curation Set: 1776; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

69

Stokes M (2006) CST Curation Set: 1777; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

70

Stokes M (2006) CST Curation Set: 1778; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

71

Stokes M (2006) CST Curation Set: 1779; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

72

Stokes M (2006) CST Curation Set: 1636; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

73

Stokes M (2006) CST Curation Set: 1637; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

74

Stokes M (2006) CST Curation Set: 1124; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

75

Stokes M (2006) CST Curation Set: 1093; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

76

Stokes M (2006) CST Curation Set: 1094; Year: 2006; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

77

Stokes M (2005) CST Curation Set: 1061; Year: 2005; Biosample1/Treatment/Isotope: cell line, M059K/none/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

78

Stokes M (2005) CST Curation Set: 992; Year: 2005; Biosample1/Treatment/Isotope: cell line, M059K/UV/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

79

Stokes M (2005) CST Curation Set: 910; Year: 2005; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info